TAFRO syndrome requiring combined IL 6 and IL 1 inhibition: a case report
This case highlights the diagnostic and therapeutic challenges posed by iMCD TAFRO. In cases with refractory disease despite targeted IL-6 inhibition, additional IL-1 inhibition might pose a further treatment option.
Authors
- Carl Hinrichs (ORCID: https://orcid.org/0000-0002-5038-0350)
- Lars Trenkmann
- Hildrun Haibel (ORCID: https://orcid.org/0000-0002-5180-1831)
- Ahmad Wael Sultan
- Thomas Schneider (ORCID: https://orcid.org/0000-0003-1125-0518)
- Leif G. Hanitsch (ORCID: https://orcid.org/0000-0002-8181-0093)
- Rasmus Leistner (ORCID: https://orcid.org/0000-0002-1225-9023)
- Eva Grießhammer
- Ilske Oschlies
Institutions
- Humboldt-Universität zu Berlin (DE)
- University Hospital Schleswig-Holstein (DE)
- Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
- University of Lübeck (DE)
Publication Details
- Journal
- Frontiers in Immunology
- Published
- 2026-01-06
- DOI
- https://doi.org/10.3389/fimmu.2025.1729525
- Primary Topic
- Viral-associated cancers and disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00